Aridis Receives FDA Feedback on Single Confirmatory Phase 3 Study of AR-301 and the Clinical Study Design

(24/7 MARKET NEWS) – Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) stated, this morning, that it received FDA on the Company’s proposed single confirmatory Phase 3 study of investigational monoclonal antibody candidate AR-301, which is being developed as an adjunctive therapy in combination with standard of care (SOC) antibiotics for the treatment of pneumonia caused by Gram-positive bacteria Staphylococcus aureus (S. aureus) in mechanically ventilated hospitalized patients.

Aridis Pharmaceuticals is trading at $0.348, up $0.163 (+88.11%), on 26.39M shares traded.

Its 52-week range is $0.15 to $2.77. It doesn’t have much resistance from 40 to 50-cents, so, if trading volume picks up, this could go much higher.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to or for further information.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist